Diligence memo · auto-generated · as of July 2, 2026
Lattice Biologics Ltd.
Lattice Biologics Ltd. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Lattice Biologics Ltd. operates in Biotechnology, based in SCOTTSDALE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lattice Biologics Ltd. has raised $9.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.4M on 2015-12-23.
Most recent recorded round closed around 2017-01-23.
Valuation (modeled)modeled
Provath models Lattice Biologics Ltd. at approximately $13M (range $405K–$73M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.06× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 3 months.
Last raise 9.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 54% of Biotechnology peers (4293 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.